Adhera Receives European Patent Covering MLR-1019 and Derivatives for Treating Dyskinesias
October 04, 2021 09:15 ET
|
Adhera Therapeutics, Inc.
Baton Rouge, LA, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce that a new...
Adhera Therapeutics Provides Insight on Corporate Strategy, Development of Parkinson’s Disease and Type 1 Diabetes Drugs
September 13, 2021 10:28 ET
|
Adhera Therapeutics, Inc.
Baton Rouge, LA, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, today provides shareholders an...
Adhera Therapeutics Appoints Dr. Andrew Reaume to Board of Directors
September 09, 2021 09:05 ET
|
Adhera Therapeutics, Inc.
Baton Rouge, LA, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce the...
Adhera Therapeutics Signs Exclusive License Agreement with Melior Pharmaceuticals I for New Type 1 Diabetes Drug Candidate
August 24, 2021 09:20 ET
|
Adhera Therapeutics, Inc.
Adhera to develop MLR-1023 as a new drug for Type I diabetes with a focus on C-peptide positive patients (~320,000 – 480,000 patients in U.S.)Laboratory and clinical research support MLR-1023 as the...
Adhera Signs Definitive License Agreement with Melior Pharmaceuticals II for New Parkinson’s Disease Drug Candidate
July 29, 2021 09:00 ET
|
Adhera Therapeutics, Inc.
Adhera to develop MLR-1019 (armesocarb) as a new class of drug for Parkinson’s Disease (PD), representing the only drug to address both movement and non-movement symptoms of PDArmesocarb is the active...
Adhera Therapeutics Signs Letter of Intent with Melior Pharmaceuticals II to Acquire a New Class of Drug for Parkinson’s Disease
June 07, 2021 08:45 ET
|
Adhera Therapeutics, Inc.
Adhera to acquire and develop MLR-1019 (armesocarb), the API in mesocarb – a drug previously sold in Europe for 37 years – for Parkinson’s DiseaseMLR-1019, a Phase 2-ready product, could have...
Adhera Therapeutics Appoints Trond K. Waerness to Board of Directors
April 23, 2021 09:00 ET
|
Adhera Therapeutics, Inc.
Baton Rouge, LA, April 23, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera Therapeutics" or the "Company"), a clinical stage biopharmaceutical company engaged in the...
Adhera Therapeutics Announces Termination of Tender Offer for Preferred Stock
September 26, 2019 16:19 ET
|
Adhera Therapeutics, Inc.
RESEARCH TRIANGLE PARK, NC, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX), a specialty pharmaceutical company leveraging technology to commercialize unique therapies and...
Adhera Therapeutics Announces Termination of Tender Offer for Warrants
July 02, 2019 16:15 ET
|
Adhera Therapeutics, Inc.
RESEARCH TRIANGLE PARK, NC, July 02, 2019 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX), a specialty pharmaceutical company leveraging technology to commercialize unique therapies and...
Adhera Therapeutics Appoints Nancy Phelan as Chief Executive Officer
April 04, 2019 09:15 ET
|
Adhera Therapeutics, Inc.
RESEARCH TRIANGLE PARK, NC, April 04, 2019 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX), a specialty pharmaceutical company leveraging technology to commercialize unique therapies and...